why are there greened-out notables? What does this mean?
weird how NO ONE/nation/'enemy' has the Epstein/Maxwell/Nygard client lists, travel records, financial statements, eh?
Why can't any world leader or 'presidential candidate' simple read a list of names and post mirrored urls of the list and associated evidence, and then end the event. Just state that, and force the world media to scramble over it?
uh huh
and financial records, and mil surveillance of all air traffic, and the fact that a passport was not required for USAUSVI air travel, and the sat surveillance of everything, and the pilots, drivers, boatsmen, secret service, royal, and high net worth protection details that were in tow, with cellphones, smart watches etc?
> it will pay $75 million to settle a lawsuit
pay to whom? victim families? nah, USVI 'charities'.
https://twitter.com/_/status/1706701034536550706
Disclose.tv
@disclosetv
NOW - UK Home Secretary: "Multiculturalism has failed."
>Give this Anon a shekel.
fuck that. anon will take real physical property with water and resources, gold, silver, or unvaxxed dear, goats, & bison though
https://twitter.com/theosanderson/status/1706327002154668430
Theo Sanderson
@theosanderson
📄 📄 Our molnupiravir work is now out after peer-review! We definitively demonstrate that molnupiravir has resulted in viable SARS-CoV-2 viruses with significant numbers of mutations, in some cases with onwards transmission of mutated viruses.
nature.com
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
Nature - A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
10:17 AM · Sep 25, 2023
https://www.nature.com/articles/s41586-023-06649-6
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
Abstract
Molnupiravir, an antiviral medication that has been widely used against SARS-CoV-2, acts by inducing mutations in the virus genome during replication. Most random mutations are likely to be deleterious to the virus, and many will be lethal, and so molnupiravir-induced elevated mutation rates reduce viral load1,2. However, if some patients treated with molnupiravir do not fully clear SARS-CoV-2 infections, there could be the potential for onward transmission of molnupiravir-mutated viruses. Here we show that SARS-CoV-2 sequencing databases contain extensive evidence of molnupiravir mutagenesis. Using a systematic approach, we find that a specific class of long phylogenetic branches, distinguished by a high proportion of G-to-A and C-to-T mutations, appear almost exclusively in sequences from 2022, after the introduction of molnupiravir treatment, and in countries and age-groups with widespread usage of the drug. We identify a mutational spectrum, with preferred nucleotide contexts, from viruses in patients known to have been treated with molnupiravir and show that its signature matches that seen in these long branches, in some cases with onwards transmission of molnupiravir-derived lineages. Finally, we analyse treatment records to confirm a direct association between these high G-to-A branches and the use of molnupiravir.